Article | December 2, 2020

Investment In Internal Process Development And Manufacturing Enables Rapid Product Development

By Alex Meola, Scientist II, Homology Medicines

Homology  1

Speed to the clinic and patient safety are important goals when working to bring novel genetic therapies to patients. To achieve these goals, Homology Medicines decided to invest in internal development and manufacturing operations not long after the Company’s founding, which included the construction of a 25,000 sq ft GMP manufacturing facility adjacent to its headquarters. This allowed for efficient collaboration, integration, and iteration as Homology developed a commercial platform process that supports both gene therapy and gene editing constructs. By focusing on early product engagement with research, a dedicated process development team, and a collaborative feedback loop with its internal manufacturing facility, Homology established the perfect trifecta for rapid learning.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: